Astellas ISR Portal

At this time, Astellas is prioritizing the review of new Investigator Sponsored Research concepts related to the use of Astellas products in
the management of COVID-19. Please send all COVID-19 concepts to isrdevsupport@astellas.com.

We are accepting new applications for ISR proposals. Applications for proposals for the following products by region will be considered and may be submitted using this website:
      • EMEA enzalutamide, gilteritinib (France, Spain, Italy, Germany, UK, Netherlands, Austria, Belgium, Denmark, Ireland, Sweden)
      • USA:
      • enfortumab vedotin (proposals will be reviewed jointly by Astellas and Seattle Genetics)
      • enzalutamide (proposals will be reviewed jointly by Astellas and Pfizer)
      • gilteritinib
      • mirabegron
      • isavuconazonium sulfate
      • Canada: enzalutamide
      • Brazil and Colombia: enzalutamide
      • Asia Oceania: febuxostat, enzalutamide, tacrolimus extended release and mirabegron.
      • Japanese users: Please go to https://www.astellas.com/jp/isr/program.html for instructions.

Please do not use this website to report safety information or product complaints.To report safety information or product complaints about an Astellas medicine please email (according to region) to:
For EMEA: safety-EU@astellas.com ; for USA: safety-US@astellas.com ; or for Asia/Oceana: Safety-JP@astellas.com.

Welcome!

This is your place to manage all of your investigator-sponsored research with Astellas.